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ABSTRACT 
Background: Pathogenesis of cutaneous extraintestinal manifestations (EIM) in inflammatory bowel 
disease (IBD) remains elusive. Efficacy of anti-TNF agents suggests TNF-dependent mechanisms. The 
role of other biologics such as anti-integrins or JAK-inhibitors is not yet clear.  
Methods: We performed immunohistochemistry for TNFα, NFκB, STAT1/STAT3, MAdCAM1, 
CD20/68, caspase 3/9, IFNγ, Hsp-27/70 on 240 intestinal (55 controls, 185 IBD) and 64 skin biopsies 
(11 controls, 18 Erythema nodosum (EN), 13 Pyoderma gangenosum (PG), 22 psoriasis). A 
semiquantitative score (0-100%) was used for evaluation. 
Results: TNFα was upregulated in intestinal biopsies from active Crohn`s disease (CD) vs. controls 
(36.2 vs. 12.1, p<0.001), but not ulcerative colitis (UC: 17.9). NFκB however was upregulated in 
intestinal biopsies from both active CD and UC (43.2 and 34.5 vs. 21.8, p<0.001 and p=0.017). TNFα 
and NFκB were overexpressed in skin biopsies from EN, PG and psoriasis. No MAdCAM1 
overexpression was seen in skin tissues, while it was upregulated in active UC vs. controls (57.5 vs. 
35.4, p=0.003). STAT3 was overexpressed in the intestinal mucosa of active and non-active IBD, while 
a similar upregulation was seen in skin biopsies from EN (84.7 vs. 22.3, p<0.001) and PG (60.5 vs. 
22.3, p=0.011), but not in psoriasis. Caspase 3 and CD68 overexpression in skin biopsies distinguished 
EN/PG from psoriasis and controls. 
Conclusions: Upregulation of TNFα/NFκB in EN and PG is compatible with the efficacy of anti-TNF in 
EIM management. Data on overexpressed STAT3, but not MAdCAM1 support a rationale for JAK-
inhibitors in EN and PG, while questioning the role of vedolizumab.  
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INTRODUCTION 
Inflammatory bowel disease (IBD) with the two main subtypes Crohn`s disease (CD) and ulcerative 
colitis (UC) is a chronic inflammatory disorder of the gastrointestinal tract. The etiopathogenesis of 
IBD is incompletely understood, although it is considered being a multifactorial disease, which arises 
from a complex interplay between genetic, environmental and immunological factors with an 
abnormal host immune response to environmental stimuli. (1) Different cytokines and cell 
interaction proteins have been identified as key players in IBD pathogenesis such as the TNFα-NFκB 
axis, the JAK-STAT pathway and the integrin-vascular adhesion molecule interaction. Several already 
approved drugs or investigational agents take advantage of these pathomechanisms. Anti-TNF agents 
have been successfully used for more than a decade, while anti-integrins such as vedolizumab have 
been introduced into clinical practice only recently. (2, 3) The latter target the gut-specific interaction 
between integrin α4β7 on leukocytes and the adhesion molecule MAdCAM1 on endothelial cells in 
the intestine, thereby blocking leukocyte adhesion and migration to the site of inflammation. Few if 
any systemic side effects are observed. (2, 3) Tofacitinib represents a first class oral agent inhibiting 
the Janus kinase (JAK) family of proteins, which are important mediators in inflammation. Blocking 
JAK downregulates proinflammatory cytokines such as interleukin (IL) 2, 4, 7, 9, 15 and 21 through 
the JAK-STAT pathway. (4) Efficacy has been reported for UC, but not for CD, while more specific JAK 
inhibitors such as filgotinib may also be efficacious in the latter indication. (5-7) Approval process for 
tofacitinib`s use in UC patients has been recently initiated by the US Food and Drug Administration 
(FDA). 
Extraintestinal manifestations (EIM) of IBD are common with a frequency ranging from 6 to 47%. (8-
15) Besides arthritis and stomatitis, cutaneous manifestations are among the most prevalent EIM.
(15) IBD skin lesions mainly include erythema nodosum (EN) and pyoderma gangrenosum (PG). While 
EN usually parallels intestinal disease activity, PG may or may not be associated with intestinal 
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disease. The pathomechanisms of EN and PG remain elusive, although efficacy of anti-TNF treatment 
suggests TNF-dependent mechanisms. Limited data from immunohistochemical evaluations and 
protein analyses from tissue lysates have demonstrated upregulation of several inflammatory 
cytokines such as IL 8, 17, 1β and TNFα in PG. (16, 17) Evidence for the efficacy of anti-TNF in EIM 
management is evolving. Recently, a thorough meta-analysis conducted by Peyrin-Biroulet and 
colleagues has shown response rates between 69-100% for PG and reduction of EN prevalence from 
2.4 to 0.4% with anti-TNF treatment. (18, 19) If other biological agents are efficacious in the 
treatment of EN or PG has yet to be determined. Studies evaluating the role of vedolizumab are 
under way. It is yet unclear if the gut-selective mode of action limits its efficacy to the intestine or if 
indirect beneficial effects via decrease of intestinal inflammatory load might be relevant. No data is 
available so far regarding the influence of JAK inhibitors on EIM, although tofacitinib`s efficacy has 
been shown for other auto-inflammatory disorders such as rheumatoid arthritis and psoriasis. (20, 
21) 
We herein investigated different proteins involved in intestinal and extraintestinal IBD 
manifestations aiming at elucidating similarities and differences in IBD, cutaneous EIM and psoriasis 
pathophysiology with a special focus on possible therapeutic implications such as involvement of the 
TNFα-NFκB and JAK-STAT pathway as well as the integrin-MAdCAM interaction. 
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METHODS 
Study design 
In this observational single-center study, we prospectively collected intestinal and cutaneous tissue 
samples from healthy individuals and patients with IBD, cutaneous EIM and psoriasis. Sample 
collection was conducted between 2004 and 2011. All patients had previously given their written 
informed consent for tissue collection and review of patient charts. All data were anonymized. The 
study was supported by the Swiss National Science Foundation and was approved by the local ethics 
committee of the University Hospital Zurich (KEK-ZH-837). 
Patient and data collection 
All patients analyzed in this study were treated for IBD and/or inflammatory skin disease such as EN, 
PG or psoriasis at the University Hospital Zurich, Switzerland. Diagnosis of UC and CD had been 
previously established according to the current ECCO guidelines. (22, 23) Inflammatory skin lesions 
had all been diagnosed by a dermatologist. Intestinal samples from healthy controls were collected 
at regular screening colonoscopies at the University Hospital Zurich. Patients had to be older than 18. 
Endoscopic disease activity was assessed using the Mayo Clinic endoscopy subscore for UC and the 
CD endoscopic index of severity (CDEIS) for CD, respectively. (24-26) A score of ≥1 (Mayo Score) and 
≥3 (CDEIS) was considered as active disease. (25, 27) Patients were excluded for: i) biological 
treatment with anti-TNF within the last 8 weeks, ii) ongoing treatment for inflammatory skin disorder 
(topical or systemic), iii) concomitant autoimmune disorders such as systemic lupus erythematodes 
or vasculitis, and iv) concomitant skin disorder such as eczema, atopic dermatitis or paradoxical anti-
TNF induced skin lesions. Clinical data were retrieved from paper-based and electronic patient 
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records.  The following data were collected: patient demographics (gender, age), disease history, 
previous and current medications and comorbidities. For this purpose, a standardized spreadsheet 
was used (Supplementary Table 1). 
Tissue sample collection 
For intestinal samples, biopsies were taken from the terminal ileum (TI), cecum, and colon using a 
needle forceps. For skin samples, biopsies were taken from the affected lesion using a 4-6 mm 
surgical punch that collected epidermis, dermis and the upper subcutis. For healthy control skin, 
fresh, non-affected and non-inflamed skin of unrelated surgical excisions was used. Biopsies were 
formalin fixed-paraffin embedded and stored at -80°C for further use. 
Tissue microarray and immunostaining 
Tissue microarrays (TMA) were constructed using formalin fixed paraffin-embedded tissue blocks, 
which had been punched out from ileal, cecal, colonic, sigmoid or skin tissue by a tissue cylinder 
(0.6mm in diameter), as it had been previously described. (28, 29) Immunohistochemical staining 
was performed using the automated system BOND RX (Leica Biosystems). TMA sections were 
deparaffinized and rehydrated in dewax solution (Leica Biosystems). Immunohistochemistry was 
carried out for the TNF-NFκB (TNFα, NFκB) and JAK-STAT pathway (STAT1, STAT3) as well as the 
MAdCAM-integrin interaction (MAdCAM1), which all represent targets of IBD treatment modalities. 
We further investigated markers for B lymphocytes (CD20), macrophages (CD68), Th1-cytokine 
mediated disease (IFNγ), apoptosis (caspase 3 and 9), and inflammation-induced antiapoptotic 
factors (Hsp-27/70). The following primary antibodies were used: TNFα (Abcam, ab6671, dilution 
1:50), NFκB p65 (Abcam, ab32360, dilution 1:100), MAdCAM1 (clone CA102.2CI, Affimetrix BMS170, 
dilution 1:1000), STAT1 (R&D Systems, MAB1490, dilution 1:50), STAT3 (Abcam, ab50761-100, 
dilution 1:100), CD20 (Ventana Roche, prediluted), CD68 (Ventana Roche, prediluted), caspase 3 
(Abcam, ab4051, dilution 1:200), caspase 9 (Invitrogen, PA5-17913, dilution 1:200), IFNγ (BD 
Biosciences, 560371, dilution 1:100), Hsp-27 (Leica Biosystems, NCL-HSP27, dilution 1:40), and Hsp-
70 (Enzo Life Sciences, dilution 1:100).  Antibody was detected with the Bond Polymer Refine 
Detection kit (Leica Biosystems), using DAB (3-3’-Diaminobenzidine) as chromogen and following the 
manufacturer’s instructions. A semiquantitative scoring system ranging from 0 to 100% (5% intervals) 
was used for evaluation of immunostaining. (29, 30) Scoring was performed by two reference 
pathologists in the field of tissue microarrays (AL, HD). TMA review was blinded. All samples and 
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controls were run in duplicate. Failure of analysis occurred in 15.1% (796/5040 spots) of all 
gastrointestinal samples and in 9.4% (72/765 spots) of skin samples. Reasons for such failure were 
missing samples (empty spots on microarray) or TMA technology. 
Statistical analysis 
For all statistical analyses, IBM software SPSS (version 22.0.0, 2013 SPSS Science, Inc., Chicago, IL) 
was used. Each biopsy sample was analyzed individually. Metric data are presented as means and 
standard deviation (SD). Categorical data are depicted as percentage of the group total. For 
comparisons between continuous variables, two-sample t-test and Mann-Whitney-U test were used 
depending on whether data were normally distributed or not. A two-sided p-value of <0.05 was 
regarded as statistically significant.  
Downloaded from https://academic.oup.com/ecco-jcc/advance-article-abstract/doi/10.1093/ecco-jcc/jjx158/4647660
by University of Zurich user
on 07 December 2017
Manuscript Doi: 10.1093/ecco-jcc/jjx158 
RESULTS 
Tissue samples 
A total of 304 intestinal and skin tissue samples were collected. 240 intestinal biopsies were taken 
from a total of 106 patients. These samples showed active endoscopic IBD in 108 cases and 
endoscopic inactivity in 77 cases. 55 intestinal biopsies were taken from 29 healthy controls. 64 skin 
samples were collected from 64 patients, 53 patients had an inflammatory skin disorder (18 EN, 13 
PG, 22 psoriasis), while 11 patients (controls) had normal skin. 2 of the 53 patients with an 
inflammatory skin disorder (1 EN and 1 PG) had corresponding intestinal biopsies showing active 
ileocecal CD (for EN) and active UC pancolitis (for PG). In detail, the following samples were analyzed: 
74 from TI (19 HC, 19 CD inflamed, 13 CD not inflamed, 23 UC not inflamed), 79 from the cecum (21 
HC, 17 CD inflamed, 13 CD not inflamed, 28 UC not inflamed), 57 from the sigmoid colon (15 HC, 42 
UC inflamed), 30 from the colon (30 UC inflamed), and 64 from the skin (11 HC, 18 EN, 13 PG, 22 
Psoriasis).  
Patient demographics 
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156 (51.3%) samples were taken from male patients, mean age was 43.7 years (SD 9.7).  Patients 
with PG were significantly older, and there were significantly less males in the EN group, the other 
groups were comparable regarding gender and age. Of the 185 IBD intestinal samples, 36 showed 
endoscopically active CD, 26 non-active CD, 72 endoscopically active UC and 51 showed non-active 
UC. Of the 72 samples with endoscopic UC activity, 31 UC samples were collected from patients with 
pancolitis, while 41 from patients with left sided UC. All of the 36 samples with active CD were taken 
from ileal (n=19) or cecal (n=17) disease, while the samples for inactive CD were collected from non-
inflamed TI (n=13) or non-affected cecum (n=13). Two IBD patients reported a previous anti-TNF 
treatment, which was however stopped more than 8 weeks before biopsy. At the time of skin biopsy, 
none of the patients with skin disorders were treated with systemic or topical anti-inflammatory 
drugs. None of them had a history of a previous use of biological treatment. None of the patients 
with psoriasis had underlying IBD. Table 1 summarizes demographic data and prior medication of all 
patients and the respective subgroups.  
Expression of the TNFα/NFκB pathway in intestinal disease and cutaneous manifestations 
Subepithelial TNFα expression was significantly higher in active CD compared to controls (36.2 vs. 
12.1, p<0.001), but was not elevated in inactive CD (20.9 vs. 12.1, n.s.). Difference between active 
and inactive CD was also significant (p=0.019). No difference was seen regarding TNFα expression in 
UC patients (regardless of disease activity) vs. controls (17.9 and 13.1 vs. 12.1, n.s.). TNFα expression 
was significantly higher in CD than in UC (36.2 vs. 17.9, p=0.001). However, NFκB, a downstream 
signal of TNF was upregulated in both active UC (34.5) and active CD (43.2) vs. controls (21.8, 
p=0.017, p<0.001) with no significant differences between the two diseases. In inactive disease, NFκB 
was not significantly elevated neither in CD nor in UC. Similarly to what was seen in intestinal 
samples, subepithelial TNFα was overexpressed in all inflammatory skin disorders (EN 25.6, PG 37.7, 
psoriasis 14.7) compared to controls (3.2, p<0.001, p=0.001, and p=0.001). PG demonstrated even 
higher TNFα expression levels than psoriasis (37.7 vs. 14.7, p=0.022), while for EN vs. psoriasis at 
least a clear trend was seen (25.6 vs. 14.7, p=0.052). Similar results were observed for NFκB 
expression with however no difference between PG and psoriasis, while upregulation of NFκB was 
significant in EN vs. psoriasis (p=0.002). NFkB expression was 41.8 in EN, 25.0 in PG, 14.3 in psoriasis 
and 5.9 in healthy controls. For details regarding TNFα and NFκB expression see Figures 1 and 2. 
Expression of MAdCAM1 
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MAdCAM1 was upregulated in inflamed intestinal tissue. Compared to healthy controls, active UC 
showed a significant MadCAM1 overexpression (57.5 vs. 35.4, p=0.003). MadCAM1 was also 
upregulated in active UC when compared to inactive UC (57.5 vs. 39.3, p=0.027). Expression from 
intestinal samples with active CD did not show significant differences when compared to healthy 
controls (30.8 vs. 35.4). In contrast to the upregulation of MAdCAM1 in UC patients, no 
overexpression compared to healthy controls was seen for EN, PG, and psoriasis. In fact, expression 
levels of MAdCAM1 were below the threshold of 10% in all samples with inflammatory skin 
disorders. Figure 3 shows representative tissue samples from the intestine (IBD and healthy controls, 
Fig. 3a) and inflammatory skin diseases (Fig. 3b) stained for TNFα and MAdCAM1. Representative 
tissue samples for inactive intestinal disease stained for TNFα and MAdCAM1 are depicted in 
Supplemental Figure 1. For expression levels of intestinal samples see Supplemental Figure 2. 
Expression of STAT proteins in intestinal disease and cutaneous manifestations 
STAT3, which is involved in the JAK-STAT pathway and which can be blocked by JAK inhibitors such as 
tofacitinib, was elevated in both active and inactive CD (73.4 and 81.5 vs. 60.5, p=0.028 and 
p=0.002). Same results were seen for active and inactive UC (79.2 and 72.7 vs. 60.5, p<0.001 and 
p=0.012). There was no difference between active and inactive disease nor between UC and CD 
(n.s.). Of note, same significant upregulation of STAT3 was observed in EN (84.7) and PG (60.5) 
compared to controls (22.3) and psoriasis (26.8). STAT3 was even higher expressed in EN compared 
to PG (p=0.033). For details see Figure 4. Although there was also some significant overexpression of 
STAT1 in EN, absolute numbers (EN 17.1, PG 1.4, psoriasis 2.9, controls 0.0)) were considerable lower 
than those seen for STAT3.  
Expression of other proteins 
We assessed the expression of several other proteins involved in inflammatory processes and cell 
injury. Caspase 3 upregulation significantly distinguished PG and EN from healthy controls and 
psoriasis: Caspase 3 was higher in both EN (20.0) and PG (17.7) vs. in psoriasis (2.8, p<0.001 and 
p=0.002) and in controls (0.9, p<0.001, and p<0.001). Caspase 9 was overexpressed in EN (13.1), PG 
(10.9), and psoriasis (6.0) compared to controls (2.3), although upregulation in PG was not significant 
due to a high variation. Nonetheless, these results highlight caspases as potential targets in EIM 
management. While no upregulation of IFNγ in intestinal disease nor in skin lesions was seen, there 
was a significant overexpression of CD68 in inflammatory skin disorders (EN 54.7, PG 32.3, psoriasis 
10.2 vs. controls 3.9, p<0.001, p<0.001, and p=0.003, respectively). Upregulation was significantly 
higher in EN compared to PG (p=0.042) and psoriasis (p<0.001). Difference between PG and psoriasis 
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was also significant, highlighting the possible pathogenic role of CD68 and therefore macrophages in 
PG and EN pathophysiology, but not in psoriasis. However, absence of CD68 overexpression in 
intestinal IBD, as well as low absolute numbers of CD20 (controls 0.0, EN 2.2, PG 2.1, psoriasis 1.4) 
and Hsp-27 expression (controls 5.9, EN 11.8, PG 6.8 and psoriasis 4.5) do not allow drawing clear 
conclusions. Hsp-70 did not show any overexpression in the skin samples (controls 8.2, EN 9.4, PG 8.2 
and psoriasis 5.6).  Expression levels of Caspase 3, Caspase 9, Hsp-27, Hsp-70, CD20, CD68 and IFNγ 
are depicted in Supplemental Figure 3.  
DISCUSSION 
This single-center observational study with assessment of protein expression patterns in IBD, 
cutaneous EIM and psoriasis compared to healthy controls shows similar upregulation of TNFα and 
STAT3 in both intestinal and cutaneous disease, but absence of MAdCAM1 overexpression in 
inflammatory skin disorders. TNFα and STAT3 are both considerably upregulated in EN and PG with 
even higher expression levels compared to psoriasis. Protein expression patterns of EN and PG show 
many similarities with only few differences revealing important therapeutic implications. 
The TNFα-NFκB axis is overexpressed in both intestinal disease as well as in inflammatory skin 
disorders with an even more pronounced upregulation in PG and EN compared to psoriasis. TNFα 
was recognized as an important inflammatory parameter in different autoimmune diseases including 
IBD and psoriasis many years ago. Anti-TNF take advantage of this canonical inflammatory pathway. 
They have been successfully introduced in the last decade and have changed IBD management 
dramatically. Their potential beneficial role in EIM management had been first proposed based on 
small case series and case reports. (31) Very recently, Peyrin-Biroulet and colleagues nicely 
summarized their efficacy in a meta-analysis demonstrating high response rates for PG (69-100%) 
and EN (prevalence reduction from 2.4 to 0.4%). Complete remission rates for PG were however 
lower (25-100%). (18, 19) PG actually is the only cutaneous IBD manifestation where a randomized 
controlled trial is available for showing clinical improvement in 69% and a complete remission in 25% 
of the patients after an induction treatment with infliximab. (32) Further data from the Swiss IBD 
cohort study supports this data demonstrating improvement rates of 60% for PG and 80% for EN. 
(33) This has led to the current understanding of a TNF-dependent pathogenesis in cutaneous EIM. 
While in PG samples indeed TNFα upregulation has been reported previously, no such data is 
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available for EN. Our data of overexpression in both PG and EN, and even higher levels compared to 
psoriasis, are compatible with the known efficacy of anti-TNF efficacy in cutaneous EIM. (16) 
Although TNFα-NFκB axis was upregulated in both CD and UC with a particular overexpression of 
intracellular NFκB, TNFα was actually only significantly increased in intestinal samples from active CD, 
but not in UC. There are three possible explanations: 1) The finding that TNFα levels in the lamina 
propria are indeed higher in CD than UC has been already described more than two decades ago. 
(34) 2) For detection of the small difference between healthy controls and UC our study was 
probably underpowered. 3) Other factors such as bacterial products (e.g. lipopolysaccharides, LPS) 
can lead to NFκB upregulation independent from TNFα, so (over)expression of the two proteins do 
not necessarily go in parallel.  
The anti-integrin vedolizumab has been introduced into clinical practice very recently. Data from 
randomized controlled trials demonstrated vedolizumab`s efficacy in both CD and UC.  (2, 3) 
Vedolizumab`s role in EIM management has not yet been defined. Its gut-selective mechanism 
advocates against, while some preliminary data presented at recent congresses advocate for an at 
least partial efficacy in the treatment of EIM. (35) In consistence with the literature, we herein report 
on isolated MAdCAM1 expression in the inflamed intestine, but not in inflammatory skin disorders, 
which makes a direct effect on cutaneous EIM extremely unlikely. If anyhow, vedolizumab might 
have a role in EIM management by treating intestinal disease activity in EIM that parallels IBD. 
The third biologic, which is currently reviewed by the US FDA for treatment in UC patients, is the JAK 
inhibitor tofacitinib, which has been successfully used in other diseases such as rheumatoid arthritis 
and psoriasis. (20, 21) Tofacitinib inhibits the JAK-STAT pathway, which incites pro-inflammatory 
signals. Biopsies from active intestinal disease and inflammatory skin disorders demonstrated similar 
results regarding STAT3 overexpression in our patient cohort. Difference between healthy controls 
and inflamed tissue was even more prominent in skin biopsies. Of note, STAT3 was significantly more 
upregulated in PG/EN than in psoriasis shedding light on the potential benefit from JAK inhibition in 
those patients. Clinical data is not available so far, but our findings make a therapeutic response to 
JAK inhibitors very likely. Given tofacitinib`s current blackbox warning for serious infections, possible 
systemic side-effects from pan-JAK inhibitors should be kept in mind, which however occur less 
frequent with more specific JAK inhibitors such as filgotinib. 
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With the microarray approach, several other interesting targets for EIM management have been 
identified by screening markers for B-lymphocytes (CD20), macrophages (CD68), apoptosis (caspase 
3 and 9) and inflammation-induced anti-apoptotic factors (Hsp-27/70). Both caspase 3 and CD68 
were overexpressed in EN and PG compared to healthy controls and psoriasis highlighting the 
overlap between cutaneous EIM with a protein expression profile distinct from other inflammatory 
skin diseases. Anti-caspases are currently tested in liver diseases (emricasan in non-alcoholic 
steatohepatitis, NCT02686762), while no data is available so far for EIM or IBD.  
Our study has several strengths, but also some limitations. To the best of our knowledge, it is so far 
the only study investigating protein expression patterns in IBD and cutaneous EIM in IBD comparing 
them to healthy controls and psoriasis. Microarray is a widely used and reliable tool to study 
expression of various proteins. Variation due to TMA technology has been limited using only 
duplicate samples. None of the patients with inflammatory skin disorders were treated with neither 
topical nor systemic anti-inflammatory drugs, which makes the TMA results more reliable. In 
addition, previous anti-TNF treatment was reported in two IBD patients only, and treatment was 
stopped more than 8 weeks before study evaluation, making interference with biopsy results less 
likely. All TMA were analyzed by experts in TMA evaluation and involvement of only two pathologists 
has limited inter-observer variability. We were able to include 13 patients with PG despite its rarity 
(prevalence 2% of Swiss IBD population, incidence 0.63/100`000) due to the close collaboration with 
our Department of Dermatology and a study enrolment over several years. (15, 36) A limitation of 
the TMA technology is that tissue sample heterogeneity is not completely taken into account. The 
study was cross-sectional without any follow-up, therefore changes in expression levels in response 
to any biological treatment could not be assessed. The study relied on protein expression levels only 
and did not include analysis of mRNA levels. A further drawback of this study is that we only 
identified MAdCAM1 overexpression in active UC, but not active CD samples. This might be due to 1) 
the low number of samples from active CD (n=36) compared to the relatively higher number of active 
UC (n=72) and 2) the inclusion of non-severe CD cases given the very low cut-off of CDEIS ≥3. (37)  
While upregulation of TNFα in cutaneous EIM compared to healthy controls is compatible with the 
known efficacy of anti-TNF in EIM management, the lack of MAdCAM1 overexpression in the human 
skin, even in the context of inflammation, questions the role of vedolizumab in EIM treatment. It`s 
only effect might be indirect through inducing and maintaining intestinal disease remission in those 
EIM paralleling IBD activity. Data on upregulated STAT give a rationale for JAK-inhibitors in both EN 
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and PG management, particularly in the current context of missing clinical studies. Data from 
randomized controlled trials evaluating the effect of anti-integrins and JAK-inhibitors on EIM are 
however urgently needed. 
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TABLES: 
All samples 
n=304 
Intestinal 
samples 
from IBD 
N=185 
Skin 
samples 
from EN 
N=18 
Skin 
samples 
from PG 
N=13 
Skin 
samples 
from 
Psoriasis 
N=22 
Skin and 
intestinal 
samples 
from 
Controls 
N=66 
Age 
- mean in years 
(SD) 
43.7 (9.7) 41.9 (14.5) 43.8 (20.7) 61.0 (17.4) 48.7 (16.3) 43.1 (10.6) 
Gender 
males 156 (51.3%) 101 (54.6%) 5 (27.8%) 6 (46.2%) 12 (54.5%) 32 (48.5) 
Concurrent medications 
- none 
- 5-ASA 
- topical steroids 
- syst. steroids 
- antibiotics 
- AZA 
- Antihistamines 
- Biologics 
- NSAR 
164 (53.9%) 
107 (35.2%) 
15 (4.9%) 
21 (6.9%) 
10 (3.3%) 
9 (3.0%) 
4 (1.3%) 
0 (0.0%) 
3 (1.0%) 
50 (27.0%) 
106 (57.3%) 
15 (8.1%) 
21 (11.4%) 
8 (4.3%) 
9 (4.9%) 
4 (2.2%) 
0 (0.0%) 
1 (0.5%) 
18 (100%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
13 (100%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
22 (100%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
61 (92.4%) 
1 (1.5%) 
0 (0.0%) 
0 (0.0%) 
2 (3.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
2 (3.0%) 
Previous biological 
treatment 
- anti-TNF 
- vedolizumab 
- JAK inhibitor 
2 (0.7%)* 
0 (0.0%) 
0 (0.0%) 
2 (1.1%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
0 (0.0%) 
Surgical history 2
+ 
(0.7%) 2
+ 
(1.1%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
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Table 1: demographic data and prior medication. * Treatment was stopped 8 weeks before biopsies, 
+ ileocecal resection (1), partial colectomy (1). 5-ASA, aminosalicylates; AZA, azathioprine; EN, 
erythema nodosum; IBD, inflammatory bowel disease; NSAR, non-steroidal antirheumatic agent; PG, 
pyoderma gangrenosum. 
FIGURE LEGENDS: 
Figure 1: Mean TNF expression in intestinal and skin tissue. Standard error of the mean bars are 
shown. P-value calculated by Mann-Whitney-U test. 
Figure 2: Mean NFkB expression in intestinal and skin tissue. Standard error of the mean bars are 
shown. P-value calculated by Mann-Whitney-U test. 
Figure 3 Immunohistochemical analysis of intestinal and skin tissue TMA for TNF and MAdCAM1 
protein expression.  
a) intestinal tissue; A-C: MAdCAM1 immunostaining and D-F: TNF immunostaining; A/D) normal
colon, B/E active CD, C/F active UC. 
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b) skin tissue; A-D: MAdCAM1 immunostaining and E-H: TNF immunostaining; A/E) normal skin, B/F
erythema nodosum, C/G pyoderma gangrenosum, D/H psoriasis. 
Figure 4: Mean STAT3 expression in intestinal and skin tissue. Standard error of the mean bars are 
shown. P-value calculated by Mann-Whitney-U test. 
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Figure 1. 
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Figure 2. 
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Figure 3. 
a) 
b) 
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Figure 4. 
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